Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2016 - 2026)
Amphastar Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 13 years, most recently at $8.1 million for Q4 2025.
- For Q4 2025, Depreciation & Amortization (CF) rose 11.22% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $31.6 million, down 13.03%, while the annual FY2025 figure was $31.6 million, 12.03% up from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $8.1 million at Amphastar Pharmaceuticals, up from $7.9 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $9.8 million in Q3 2024 and troughed at $2.5 million in Q1 2021.
- A 5-year average of $5.8 million and a median of $5.3 million in 2022 define the central range for Depreciation & Amortization (CF).
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 215.9% in 2024 and fell as far as 24.84% in 2024.
- Year by year, Depreciation & Amortization (CF) stood at $2.6 million in 2021, then surged by 32.28% to $3.4 million in 2022, then surged by 180.86% to $9.7 million in 2023, then dropped by 24.84% to $7.3 million in 2024, then rose by 11.22% to $8.1 million in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for AMPH at $8.1 million in Q4 2025, $7.9 million in Q3 2025, and $8.3 million in Q2 2025.